A combination of enfortumab vedotin and pembrolizumab has shown promising results in treating patients with advanced bladder cancer, nearly doubling survival rates compared to chemotherapy. Additionally, Johnson & Johnson’s TAR-200 represents a novel treatment prospect, designed to sustain the local release of chemotherapy drug gemcitabine directly into the bladder. Breakthrough nanotechnology in the form of urea-powered nanorobots has also shown great potential, achieving a 90% reduction in bladder tumor size in a mouse model. These advances indicate a promising future for more targeted, effective, and less invasive bladder cancer treatments.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
